Get the Stockscreener App
219.26
0.53%
1.15
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $219.26, with a volume of 5.77M.
It is up +0.53% in the last 24 hours and down -4.17% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$218.11
Open:
$217.26
24h Volume:
5.77M
Relative Volume:
0.98
Market Cap:
$387.52B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
165.44
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
+2.29%
1M Performance:
-4.17%
6M Performance:
+15.07%
1Y Performance:
+28.47%
1-Day Range:
$215.88
$219.82
1-Week Range:
$209.96
$219.82
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Commerzbank Aktiengesellschaft FI Sells 39,586 Shares of AbbVie Inc. $ABBV - MarketBeat
Cullen Frost Bankers Inc. Has $88.49 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
West to Sell SmartDose 3.5mL System to AbbVie in $112.5M Deal - mychesco.com
AbbVie is a top dividend stock as drug pipelines drive payout hikes - thestreet.com
Mn Services Vermogensbeheer B.V. Has $155.25 Million Position in AbbVie Inc. $ABBV - MarketBeat
Resona Asset Management Co. Ltd. Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 18,081 Shares of AbbVie Inc. $ABBV - MarketBeat
UniSuper Management Pty Ltd Has $58.21 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Jennison Associates LLC - MarketBeat
Delta Financial Advisors LLC Purchases 4,830 Shares of AbbVie Inc. $ABBV - MarketBeat
TrueMark Investments LLC Lowers Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings - TechStock²
AbbVie Inc. $ABBV Shares Sold by Lockheed Martin Investment Management Co. - MarketBeat
Indian Patent Office rejects AbbVie patent bid for cancer drug Venetoclax; generics may enter market - domain-b.com
AbbVie Inc. $ABBV Shares Purchased by Strs Ohio - MarketBeat
AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next. - Barron's
AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week - TechStock²
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors - Yahoo Finance
2 High-Yielding Dividend Stocks That Retirees Can Rely on for Recurring Income - Finviz
March 6th Options Now Available For AbbVie (ABBV) - Nasdaq
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AbbVie (ABBV) and Acadia Healthcare (ACHC) - The Globe and Mail
AbbVie Inc. $ABBV Shares Sold by Simplicity Wealth LLC - MarketBeat
AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
RemeGen scores out-licensing triple play with AbbVie deal - thebambooworks.com
Bernstein Sticks to Their Hold Rating for AbbVie (ABBV) - The Globe and Mail
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings - TechStock²
AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play - TechStock²
Price Over Earnings Overview: AbbVieAbbVie (NYSE:ABBV) - Benzinga
Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative - Investing.com
Giant-Cell Arteritis Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys AG - Barchart.com
Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference - Morningstar
208,510 Shares in AbbVie Inc. $ABBV Purchased by Rakuten Investment Management Inc. - MarketBeat
Vest Financial LLC Has $72.41 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Migdal Insurance & Financial Holdings Ltd. - MarketBeat
AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market - Finviz
AbbVie price pierces main upward trend lineForecast today21-01-2026 - Economies.com
Bailard Inc. Acquires 16,049 Shares of AbbVie Inc. $ABBV - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV) - The Globe and Mail
Lobbying Update: $1,330,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie Inc.: How a Pharma Powerhouse Turned an Aging Blockbuster Into a Next-Gen Pipeline Machine - AD HOC NEWS
AbbVie stock slips as traders watch Epkinly data and the next earnings clock - TechStock²
Bernstein reiterates Market Perform rating on Abbvie stock at $225 target - Investing.com
Triasima Portfolio Management inc. Invests $2.80 Million in AbbVie Inc. $ABBV - MarketBeat
Vaughan David Investments LLC IL Has $77.91 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Dynasty Wealth Management LLC Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie price target raised to $275 from $270 at Berenberg - TipRanks
AbbVie Inc. $ABBV Shares Purchased by Arkadios Wealth Advisors - MarketBeat
Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail - Barchart.com
The 3 Most Reliable Dividend Stocks to Buy for Years to Come - Yahoo Finance
Understanding Momentum Shifts in (ABBV) - Stock Traders Daily
Assessing AbbVie (ABBV) Valuation After Recent Share Price Pullback - Yahoo Finance
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):